Wall Street Zen Downgrades ORTHOFIX MEDICAL (NASDAQ:OFIX) to Sell

Wall Street Zen lowered shares of ORTHOFIX MEDICAL (NASDAQ:OFIX - Free Report) from a hold rating to a sell rating in a research note released on Friday morning.

Other equities analysts have also issued reports about the stock. JMP Securities restated a "market perform" rating on shares of ORTHOFIX MEDICAL in a report on Friday, June 6th. Barrington Research upgraded shares of ORTHOFIX MEDICAL to a "strong-buy" rating and set a $16.00 price objective for the company in a report on Monday, June 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $21.50.

ORTHOFIX MEDICAL Stock Up 0.5%

Shares of OFIX traded up $0.06 during mid-day trading on Friday, reaching $11.15. The company had a trading volume of 361,458 shares, compared to its average volume of 287,188. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.50 and a current ratio of 2.71. The firm has a 50-day moving average price of $11.85 and a 200 day moving average price of $15.20. ORTHOFIX MEDICAL has a 52 week low of $10.24 and a 52 week high of $20.73. The company has a market capitalization of $436.86 million, a price-to-earnings ratio of -3.02 and a beta of 0.80.

Insider Buying and Selling

In related news, insider Aviva Mcpherron sold 3,728 shares of the firm's stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total value of $39,181.28. Following the transaction, the insider directly owned 46,322 shares of the company's stock, valued at approximately $486,844.22. This trade represents a 7.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Engine Capital Management, Lp purchased 100,000 shares of the firm's stock in a transaction on Wednesday, May 7th. The shares were acquired at an average cost of $12.31 per share, for a total transaction of $1,231,000.00. Following the completion of the acquisition, the insider owned 3,544,807 shares of the company's stock, valued at approximately $43,636,574.17. This trade represents a 2.90% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 112,250 shares of company stock valued at $1,380,970 and sold 7,620 shares valued at $91,168. 1.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On ORTHOFIX MEDICAL

Institutional investors and hedge funds have recently bought and sold shares of the business. Lazard Asset Management LLC bought a new stake in ORTHOFIX MEDICAL during the fourth quarter valued at about $45,000. US Bancorp DE raised its holdings in ORTHOFIX MEDICAL by 684.6% during the first quarter. US Bancorp DE now owns 5,673 shares of the medical device company's stock valued at $93,000 after acquiring an additional 4,950 shares during the period. KLP Kapitalforvaltning AS bought a new stake in ORTHOFIX MEDICAL during the fourth quarter valued at about $112,000. Tower Research Capital LLC TRC grew its position in shares of ORTHOFIX MEDICAL by 120.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company's stock valued at $148,000 after purchasing an additional 4,627 shares in the last quarter. Finally, Strs Ohio purchased a new position in shares of ORTHOFIX MEDICAL during the first quarter valued at about $150,000. 89.76% of the stock is owned by institutional investors.

ORTHOFIX MEDICAL Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.